Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major
Top Cited Papers
- 17 November 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 120 (20) , 1961-1968
- https://doi.org/10.1161/circulationaha.109.874487
Abstract
Background— The goal of this study was to determine the predictive value of cardiac T2* magnetic resonance for heart failure and arrhythmia in thalassemia major. Methods and Results— We analyzed cardiac and liver T2* magnetic resonance and serum ferritin in 652 thalassemia major patients from 21 UK centers with 1442 magnetic resonance scans. The relative risk for heart failure with cardiac T2* values 10 ms) was 160 (95% confidence interval, 39 to 653). Heart failure occurred in 47% of patients within 1 year of a cardiac T2* P P P P Conclusions— Cardiac T2* magnetic resonance identifies patients at high risk of heart failure and arrhythmia from myocardial siderosis in thalassemia major and is superior to serum ferritin and liver iron. Using cardiac T2* for the early identification and treatment of patients at risk is a logical means of reducing the high burden of cardiac mortality in myocardial siderosis. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00520559.Keywords
This publication has 25 references indexed in Scilit:
- Longitudinal analysis of heart and liver iron in thalassemia majorBlood, 2008
- Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonanceJournal of Cardiovascular Magnetic Resonance, 2008
- Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunctionJournal of Cardiovascular Magnetic Resonance, 2008
- MRI detects myocardial iron in the human heartMagnetic Resonance in Medicine, 2006
- Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosisBlood, 2006
- Intercentre Reproducibility of Magnetic Resonance T2* Measurements of Myocardial Iron in ThalassaemiaThe International Journal of Cardiovascular Imaging, 2005
- Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia majorBlood, 2004
- Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia RegisterThe Lancet, 2000
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorNew England Journal of Medicine, 1994
- Iron in the heartThe American Journal of Medicine, 1971